{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:01:45Z","timestamp":1789682505803,"version":"4.0.1"},"reference-count":181,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health (Ricerca Corrente)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Mesothelioma (MM) is an aggressive and lethal disease with few therapeutic opportunities. Platinum-pemetrexed chemotherapy is the backbone of first-line treatment for MM. The introduction of immunotherapy (IO) has been the only novelty of the last decades, allowing an increase in survival compared to standard chemotherapy (CT). However, IO is not approved for epithelioid histology in many countries. Therefore, therapy for relapsed MM remains an unmet clinical need, and the prognosis of MM remains poor, with an average survival of only 18 months. Increasing evidence reveals MM complexity and heterogeneity, of which histological classification fails to explain. Thus, scientific focus on possibly new molecular markers or cellular targets is increasing, together with the search for target therapies directed towards them. The molecular landscape of MM is characterized by inactivating tumor suppressor alterations, the most common of which is found in CDKN2A, BAP1, MTAP, and NF2. In addition, cellular targets such as mesothelin or metabolic enzymes such as ASS1 could be potentially amenable to specific therapies. This review examines the major targets and relative attempts of therapeutic approaches to provide an overview of the potential prospects for treating this rare neoplasm.<\/jats:p>","DOI":"10.3390\/cancers16111971","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T11:03:47Z","timestamp":1716375827000},"page":"1971","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeted Therapy in Mesotheliomas: Uphill All the Way"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8045-6838","authenticated-orcid":false,"given":"Elisa","family":"Bertoli","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"De Carlo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bortolot","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy"},{"name":"Department of Medicine, University of Udine, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0475-7399","authenticated-orcid":false,"given":"Brigida","family":"Stanzione","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1763-0335","authenticated-orcid":false,"given":"Alessandro","family":"Del Conte","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Spina","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1020-2338","authenticated-orcid":false,"given":"Alessandra","family":"Bearz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"ref_1","unstructured":"Sauter, J.L., Bueno, R., Dacic, S., Gill, R.R., Husain, A.N., Kadota, K., Ladanyi, M., Nowak, A., and Schmitt, F. (2021). WHO Classification of Tumors Editorial Board, Lyon IARC Press. [5th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Marsili, D., Terracini, B., Santana, V.S., Ramos-Bonilla, J.P., Pasetto, R., Mazzeo, A., Loomis, D., Comba, P., and Algranti, E. (2016). Prevention of Asbestos-Related Disease in Countries Currently Using Asbestos. Int. J. Environ. Res. Public Health, 13.","DOI":"10.3390\/ijerph13050494"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S1470-2045(14)71109-X","article-title":"International Agency for Research on Cancer Monograph Working Group. Carcinogenicity of fluoro-edenite, silicon carbide fibres and whiskers, and carbon nanotubes","volume":"15","author":"Grosse","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"00467","DOI":"10.1183\/23120541.00467-2023","article-title":"Reflecting real-world patients with mesothelioma in research: An interim report of baseline characteristics from the ASSESS-meso cohort","volume":"9","author":"Conway","year":"2023","journal-title":"ERJ Open Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1097\/JTO.0b013e3181f1cf2b","article-title":"Malignant pleural mesothelioma: A population-based study of survival","volume":"5","author":"Milano","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona\u00efve patients with malignant pleural mesothelioma: Results of the international expanded access program","volume":"3","author":"Santoro","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bjc.6604442","article-title":"Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: Combined analysis of two phase II trials","volume":"99","author":"Ceresoli","year":"2008","journal-title":"Br. J. Cancer."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada","volume":"23","author":"Gaafar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Popat","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2213-2600(20)30362-3","article-title":"Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): An investigator-initiated, randomised, open-label, phase 2 trial","volume":"9","author":"Stigt","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"488499","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): A multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jtho.2023.02.003","article-title":"Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients with Advanced Malignant Pleural Mesothelioma (NCT02784171)","volume":"18","author":"Piccirillo","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2010.12.004","article-title":"Retreatment with pemetrexed based chemotherapy in patients with malignant pleural mesothelioma","volume":"72","author":"Ceresoli","year":"2011","journal-title":"Lung Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.1200\/JCO.2021.39.15_suppl.8507","article-title":"JCO, meeting abstract, 2021 ASCO annual meeting I","volume":"39","author":"Fennell","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: The European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"CONFIRM trial investigators. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): A multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): An open-label, non randomised, phase 2 study","volume":"6","author":"Calabro","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S2213-2600(21)00043-6","article-title":"Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: A follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study","volume":"9","author":"Rossi","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): Results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1440-1827.2010.02534.x","article-title":"9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis","volume":"60","author":"Takeda","year":"2010","journal-title":"Pathol. Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.3389\/fonc.2020.01742","article-title":"The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review","volume":"10","author":"Rozitis","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumors","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_29","first-page":"e2100422","article-title":"Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape","volume":"6","author":"Madison","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","article-title":"Global Gene Expression Profiling of Pleural Mesotheliomas: Overexpression of Aurora Kinases and P16\/CDKN2A Deletion as Prognostic Factors and Critical Evaluation of Microarray-Based Prognostic Prediction","volume":"66","author":"Chuai","year":"2006","journal-title":"Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41416-021-01547-y","article-title":"Efficacy of CDK4\/6 inhibitors in preclinical models of malignant pleural mesothelioma","volume":"125","author":"Aliagas","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S1470-2045(22)00062-6","article-title":"Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): A single-arm, open-label, phase 2 trial","volume":"23","author":"Fennell","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/jnci\/92.8.636","article-title":"Adenovirus-Mediated p14ARF Gene Transfer in Human Mesothelioma Cells","volume":"92","author":"Yang","year":"2000","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10637-019-00840-1","article-title":"Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma","volume":"38","author":"Gluck","year":"2020","journal-title":"Investig. New Drugs"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/cncy.21928","article-title":"A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma","volume":"126","author":"Kinoshita","year":"2018","journal-title":"Cancer Cytopathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative Molecular Characterization of Malignant Pleural Mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41580-019-0155-x","article-title":"The regulation, functions and clinical relevance of arginine methylation","volume":"20","author":"Guccione","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2016.11.003","article-title":"Arginine Methylation: The Coming of Age","volume":"65","author":"Blanc","year":"2017","journal-title":"Mol. Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1111\/jcmm.15213","article-title":"PRMT5 silencing selectively affects MTAP -deleted mesothelioma: In vitro evidence of a novel promising approach","volume":"24","author":"Barbarino","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10637-008-9160-1","article-title":"A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer","volume":"27","author":"Kindler","year":"2009","journal-title":"Investig. New Drugs"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP -Deleted Cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2005.10.016","article-title":"EGFR overexpression in malignant pleural mesothelioma","volume":"51","author":"Destro","year":"2006","journal-title":"Lung Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/jso.21901","article-title":"Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: Prognostic correlations","volume":"104","author":"Rena","year":"2011","journal-title":"J. Surg. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cncr.23617","article-title":"Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma","volume":"113","author":"Jackman","year":"2008","journal-title":"Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ctrv.2010.11.004","article-title":"Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand?","volume":"37","author":"Agarwal","year":"2011","journal-title":"Cancer Treat. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/JTO.0b013e318215a07d","article-title":"Coactivation of Receptor Tyrosine Kinases in Malignant Mesothelioma as a Rationale for Combination Targeted Therapy","volume":"6","author":"Brevet","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"Pavlakis","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"30375","DOI":"10.1074\/jbc.M401218200","article-title":"Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the Receptor","volume":"279","author":"Johns","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/neuonc\/noz222","article-title":"INTELLANCE 2\/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma","volume":"22","author":"Eoli","year":"2020","journal-title":"Neuro-Oncology"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Chia, P.-L., Parakh, S., Tsao, M.-S., Pham, N.-A., Gan, H.K., Cao, D., Burvenich, I.J.G., Rigopoulos, A., Reilly, E.B., and John, T. (2020). Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma. Pharmaceuticals, 13.","DOI":"10.3390\/ph13100289"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","article-title":"AXL receptor tyrosine kinase as a promising anti-cancer approach: Functions, molecular mechanisms and clinical applications","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/onc.2010.555","article-title":"AXL regulates mesothelioma proliferation and invasiveness","volume":"30","author":"Ou","year":"2011","journal-title":"Oncogene"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/LCTT.S288535","article-title":"An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma","volume":"13","author":"Davis","year":"2022","journal-title":"Lung Cancer Targets Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/mi.2014.129","article-title":"The Axl receptor tyrosine kinase is a discriminator of macrophage function in the inflamed lung","volume":"8","author":"Fujimori","year":"2015","journal-title":"Mucosal Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1158\/0008-5472.CAN-09-2997","article-title":"R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer","volume":"70","author":"Holland","year":"2010","journal-title":"Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"8511","DOI":"10.1200\/JCO.2023.41.16_suppl.8511","article-title":"Bemcentinib and pembrolizumab in patients with relapsed mesothelioma: MIST3, a phase IIa trial with cellular and molecular correlates of efficacy","volume":"41","author":"Krebs","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","article-title":"ATR\/CHK1 inhibitors and cancer therapy","volume":"126","author":"Qiu","year":"2018","journal-title":"Radiother. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1158\/1535-7163.MCT-23-0138","article-title":"Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells","volume":"23","author":"Hirai","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_63","unstructured":"Rouleau, G.A., Merel, P., Lutchman, M., Sanson, M., Zucman, J., Marineau, C., Hoang-Xuan, K., Demczuk, S., Desmaze, C., and Plougastel, B. (2022). AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma. J. Pers. Med., 12."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/363515a0","article-title":"Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2","volume":"363","author":"Rouleau","year":"1993","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/1878-0261.12651","article-title":"Genetic alterations of malignant pleural mesothelioma: Association with tumor heterogeneity and overall survival","volume":"14","author":"Quetel","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13073-021-00931-w","article-title":"Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma","volume":"13","author":"Meiller","year":"2021","journal-title":"Genome Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of Merlin\/NF2 inactivation in tumor biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7","article-title":"Merlin differentially associates with the microtubule and actin cytoskeleton","volume":"51","author":"Xu","year":"1998","journal-title":"J. Neurosci. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1440-1827.2011.02666.x","article-title":"Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation","volume":"61","author":"Sekido","year":"2011","journal-title":"Pathol. Int."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1101\/gad.1335605","article-title":"Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin","volume":"19","author":"McClatchey","year":"2005","journal-title":"Genes. Dev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.bjc.6604002","article-title":"Nf2\/Merlin: A coordinator of receptor signalling and intercellular contact","volume":"98","author":"Curto","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Sato, T., and Sekido, Y. (2018). NF2\/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19040988"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41392-022-01191-9","article-title":"The Hippo signalling pathway and its implications in human health and diseases","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"dev196675","DOI":"10.1242\/dev.196675","article-title":"TEAD family transcription factors in development and disease","volume":"148","author":"Currey","year":"2021","journal-title":"Development"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1146\/annurev-biochem-013118-111829","article-title":"The Hippo Pathway: Biology and Pathophysiology","volume":"88","author":"Ma","year":"2019","journal-title":"Annu. Rev. Biochem."},{"key":"ref_77","first-page":"5874","article-title":"Combined mTOR\/MEK inhibition prevents proliferation and induces apoptosis in NF2-mutant tumors","volume":"23","author":"Li","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1158\/1078-0432.CCR-15-2225","article-title":"Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors","volume":"22","author":"Dolly","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1158\/1535-7163.MCT-20-0717","article-title":"Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma","volume":"20","author":"Tang","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1101\/gad.192856.112","article-title":"Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP","volume":"26","author":"Huang","year":"2012","journal-title":"Genes Dev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1158\/1541-7786.MCR-19-0914","article-title":"The YAP1 Signaling Inhibitors, Verteporfin and CA3, Suppress the Mesothelioma Cancer Stem Cell Phenotype","volume":"18","author":"Kandasamy","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"CT006","DOI":"10.1158\/1538-7445.AM2023-CT006","article-title":"First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)\/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations","volume":"83","author":"Yap","year":"2023","journal-title":"Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1158\/0008-5472.CAN-16-1839","article-title":"Differential PI3K\u03b4 Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy","volume":"77","author":"Ahmad","year":"2017","journal-title":"Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"8867","DOI":"10.1038\/s41598-020-65637-2","article-title":"Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts","volume":"10","author":"Fang","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.lungcan.2012.02.022","article-title":"Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM)","volume":"77","author":"Montero","year":"2012","journal-title":"Lung Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"101857","DOI":"10.1016\/j.tranon.2023.101857","article-title":"The highly selective and oral phosphoinositide 3-kinase delta (PI3K-\u03b4) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition","volume":"43","author":"Kalla","year":"2024","journal-title":"Transl. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: Are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.neo.2017.05.003","article-title":"Combined Inhibition of CDK4\/6 and PI3K\/AKT\/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells","volume":"19","author":"Bonelli","year":"2017","journal-title":"Neoplasia"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s10637-021-01086-6","article-title":"Phase 1 cohort expansion study of LY3023414, a dual PI3K\/mTOR inhibitor, in patients with advanced mesothelioma","volume":"39","author":"Zauderer","year":"2021","journal-title":"Investig. New Drugs."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-06-1101","article-title":"In vivo Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion","volume":"12","author":"Szlosarek","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjc.6600681","article-title":"Arginine deprivation, growth inhibition and tumour cell death: 2. Enzymatic degradation of arginine in normal and malignant cell cultures","volume":"88","author":"Philip","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaoncol.2016.3049","article-title":"Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1\u2013Deficient Malignant Pleural Mesothelioma","volume":"3","author":"Szlosarek","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1200\/JCO.2016.71.3230","article-title":"Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1\u2013Deficient Thoracic Cancers","volume":"35","author":"Beddowes","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_94","first-page":"100093","article-title":"Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1\u2013Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms","volume":"1","author":"Szlosarek","year":"2020","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"CT007","DOI":"10.1158\/1538-7445.AM2023-CT007","article-title":"Abstract CT007: Phase 2-3 trial of pegargiminase plus chemotherapy versus placebo plus chemotherapy in patients with non-epithelioid pleural mesothelioma","volume":"83","author":"Szlosarek","year":"2023","journal-title":"Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Sharma, S., Agnihotri, N., and Kumar, S. (2022). Targeting fuel pocket of cancer cell metabolism: A focus on glutaminolysis. Biochem. Pharmacol., 198.","DOI":"10.1016\/j.bcp.2022.114943"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"eaan4667","DOI":"10.1126\/scisignal.aan4667","article-title":"The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ","volume":"10","author":"Edwards","year":"2017","journal-title":"Sci. Signal."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/mc.23497","article-title":"Mesothelioma cancer cells are glutamine addicted and glutamine restriction reduces YAP1 signaling to attenuate tumor formation","volume":"62","author":"Adhikary","year":"2023","journal-title":"Mol. Carcinog."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_100","first-page":"3862","article-title":"Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)","volume":"7","author":"Argani","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/sj.bjc.6604964","article-title":"High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma","volume":"100","author":"Cheng","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_102","first-page":"1741","article-title":"Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer","volume":"19","author":"Inoue","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s10549-014-3077-5","article-title":"Mesothelin expression is associated with poor outcomes in breast cancer","volume":"147","author":"Li","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","article-title":"Discovery of mesothelin and exploiting it as a target for immunotherapy","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","article-title":"Mesothelin is not required for normal mouse development or reproduction","volume":"20","author":"Bera","year":"2000","journal-title":"Mol. Cell Biol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12943-017-0633-8","article-title":"Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells","volume":"16","author":"He","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Melaiu, O., Stebbing, J., Lombardo, Y., Bracci, E., Uehara, N., Bonotti, A., Cristaudo, A., Foddis, R., Mutti, L., and Barale, R. (2014). MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0085935"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1078-0432.CCR-05-1477","article-title":"Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer","volume":"12","author":"Hassan","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"9928","DOI":"10.1038\/srep09928","article-title":"New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1074\/jbc.M806776200","article-title":"A binding domain on mesothelin for CA125\/MUC16","volume":"284","author":"Kaneko","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol. Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00408-019-00244-1","article-title":"Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma","volume":"197","author":"Casjens","year":"2019","journal-title":"Lung"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.21037\/tcr-19-2027","article-title":"Level of mesothelin expression can indicate the prognosis of malignant pleural mesothelioma","volume":"9","author":"Feng","year":"2020","journal-title":"Transl. Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"100260","DOI":"10.1016\/j.ctarc.2020.100260","article-title":"Prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in Finland","volume":"25","author":"Vizcaya","year":"2020","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"26744","DOI":"10.18632\/oncotarget.15814","article-title":"Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma","volume":"8","author":"Inaguma","year":"2017","journal-title":"Oncotarget"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"46425","DOI":"10.18632\/oncotarget.17436","article-title":"Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: A meta-analysis","volume":"8","author":"Tian","year":"2017","journal-title":"Oncotarget"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2478\/raon-2020-0011","article-title":"Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases","volume":"54","author":"Goricar","year":"2020","journal-title":"Radiol. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1378\/chest.11-0129","article-title":"The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor","volume":"141","author":"Hollevoet","year":"2012","journal-title":"Chest"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.lungcan.2021.01.011","article-title":"Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial","volume":"154","author":"Katz","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.5301\/jbm.5000229","article-title":"Serum mesothelin, osteopontin and vimentin: Useful markers for clinical monitoring of malignant pleural mesothelioma","volume":"32","author":"Bonotti","year":"2017","journal-title":"Int. J. Biol. Mark."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1373\/jalm.2017.025015","article-title":"Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer","volume":"3","author":"Yu","year":"2018","journal-title":"J. Appl. Lab. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1164\/rccm.200807-1125OC","article-title":"Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment","volume":"179","author":"Grigoriu","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/ijc.25557","article-title":"A novel high-affinity human monoclonal antibody to mesothelin","volume":"128","author":"Ho","year":"2011","journal-title":"Int. J. Cancer."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin Immunotherapy for Cancer: Ready for Prime Time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","article-title":"Mesothelin targeted cancer immunotherapy","volume":"44","author":"Hassan","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41419-019-1711-1","article-title":"Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor","volume":"10","author":"Zhang","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","article-title":"Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers","volume":"16","author":"Hassan","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: A novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S1470-2045(22)00061-4","article-title":"Anetumab Ravtansine versus Vinorelbine in Patients with Relapsed, Mesothelin-Positive Malignant Pleural Mesothelioma (ARCS-M): A Randomised, Open-Label Phase 2 Trial","volume":"23","author":"Kindler","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"A095","DOI":"10.1158\/1535-7163.TARG-17-A095","article-title":"Abstract A095: Phase Ib Study of Anetumab Ravtansine in Combination with Pemetrexed and Cisplatin in Patients with Mesothelin-Expressing Epithelial Mesothelioma or Nonsquamous Non-Small Cell Lung Cancer","volume":"17","author":"Hassan","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-21-1181","article-title":"Phase I\/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors","volume":"28","author":"Rottey","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1158\/1078-0432.CCR-18-3476","article-title":"Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers","volume":"25","author":"Hagemann","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1002\/cncr.28875","article-title":"Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125","volume":"120","author":"Hassan","year":"2014","journal-title":"Cancer"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"208ra147","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Hassan","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1002\/cncr.33145","article-title":"Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin","volume":"126","author":"Hassan","year":"2020","journal-title":"Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"eaaz7252","DOI":"10.1126\/scitranslmed.aaz7252","article-title":"Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models","volume":"12","author":"Jiang","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.imlet.2018.01.011","article-title":"Therapeutic cancer vaccines: From initial findings to prospects","volume":"196","author":"Song","year":"2018","journal-title":"Immunol. Lett."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"13832","DOI":"10.1073\/pnas.0406035101","article-title":"Listeria-based cancer vaccines that segregate immunogenicity from toxicity","volume":"101","author":"Brockstedt","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/1078-0432.CCR-11-2121","article-title":"A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: Phase I studies of safety and immune induction","volume":"18","author":"Le","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.1158\/1078-0432.CCR-19-0070","article-title":"Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma","volume":"25","author":"Hassan","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.canlet.2018.03.032","article-title":"Immuno-modulators enhance antigen-specific immunity and anti-tumor effects of mesothelin-specific chimeric DNA vaccine through promoting DC maturation","volume":"425","author":"Chen","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Castelletti, L., Yeo, D., van Zandwijk, N., and Rasko, J.E.J. (2021). Anti-Mesothelin CAR T cell therapy for malignant mesothelioma. Biomark. Res., 9.","DOI":"10.1186\/s40364-021-00264-1"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","article-title":"Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1200\/JCO.2019.37.15_suppl.2511","article-title":"Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent","volume":"37","author":"Adusumilli","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"CT105","DOI":"10.1158\/1538-7445.AM2021-CT105","article-title":"Preliminary safety and efficacy of gavocabtagene autoleucel (gavo-cel, TC-210), a T cell receptor fusion construct (TRuC\u2122), in patients with treatment refractory mesothelin overexpressing solid tumors","volume":"81","author":"Hong","year":"2021","journal-title":"Cancer Res."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"600073","DOI":"10.3389\/pore.2021.600073","article-title":"Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study","volume":"27","author":"Hakim","year":"2021","journal-title":"Pathol. Oncol. Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: A Novel Target for Cancer Treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.celrep.2018.11.035","article-title":"Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator","volume":"25","author":"Kim","year":"2018","journal-title":"Cell Rep."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/his.13123","article-title":"Diagnostic Utility of BAP1 and EZH2 Expression in Malignant Mesothelioma","volume":"70","author":"Ushiku","year":"2017","journal-title":"Histopathology"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Mastromarino, M.G., Lenzini, A., Aprile, V., Al\u00ec, G., Bacchin, D., Korasidis, S., Ambrogi, M.C., and Lucchi, M. (2022). New Insights in Pleural Mesothelioma Classification Update: Diagnostic Traps and Prognostic Implications. Diagnostics, 12.","DOI":"10.3390\/diagnostics12122905"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","article-title":"EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: A multicentre, open-label, phase 2 study","volume":"23","author":"Zauderer","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/2767-9764.CRC-23-0276","article-title":"Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma","volume":"4","author":"Badhai","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Landman, N., Hulsman, D., Badhai, J., Kopparam, J., Puppe, J., Pandey, G.K., and van Lohuizen, M. (2024). Combination of EZH2 and ATM inhibition in BAP1-deficient mesothelioma. Br. J. Cancer.","DOI":"10.1038\/s41416-024-02661-3"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Al Khatib, M.O., Pinton, G., Moro, L., and Porta, C. (2023). Benefits and Challenges of Inhibiting EZH2 in Malignant Pleural Mesothelioma. Cancers, 15.","DOI":"10.3390\/cancers15051537"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1158\/0008-5472.CAN-08-3355","article-title":"BRCA1-associated protein 1 interferes with BRCA1\/BARD1 RING heterodimer activity","volume":"69","author":"Nishikawa","year":"2009","journal-title":"Cancer Res."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/cas.15705","article-title":"BRCA1 haploinsufficiency impairs iron metabolism to promote chrysotile-induced mesothelioma via ferroptosis resistance","volume":"114","author":"Luo","year":"2023","journal-title":"Cancer Sci."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Borchert, S., Wessolly, M., Schmeller, J., Mairinger, E., Kollmeier, J., Hager, T., Mairinger, T., Herold, T., Christoph, D.C., and Walter, R.F.H. (2019). Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5314-0"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1016\/j.jtho.2020.02.028","article-title":"The Association of BAP1 Loss-of-Function With the Defect in Homologous Recombination Repair and Sensitivity to PARP-Targeted Therapy","volume":"15","author":"Yang","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jtho.2017.03.023","article-title":"A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair","volume":"12","author":"Parrotta","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(20)30390-8","article-title":"MiST1 study group. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): An open-label, single-arm, phase 2a clinical trial","volume":"9","author":"Fennell","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_173","first-page":"100231","article-title":"Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene","volume":"2","author":"Ghafoor","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13073-019-0631-0","article-title":"Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma","volume":"11","author":"Ladanyi","year":"2019","journal-title":"Genome Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/1078-0432.CCR-23-2431","article-title":"Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial","volume":"30","author":"Passiglia","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jtho.2019.11.011","article-title":"Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma","volume":"15","author":"Mian","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2020.05.019","article-title":"NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer","volume":"146","author":"Leal","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_179","first-page":"PO.19.00048","article-title":"STRN-ALK Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment","volume":"3","author":"Gradhand","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1753466620935770","DOI":"10.1177\/1753466620935770","article-title":"Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: A case report","volume":"14","author":"Hu","year":"2020","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41588-023-01321-1","article-title":"Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity","volume":"55","author":"Mangiante","year":"2023","journal-title":"Nat. Genet."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/11\/1971\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:46:45Z","timestamp":1760107605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/11\/1971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":181,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["cancers16111971"],"URL":"https:\/\/doi.org\/10.3390\/cancers16111971","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]}}}